Nintedanib(BIBF1120)相关信息

costa_na · 发表于 2014-7-4 14:41:16

Nintedanib (BIBF 1120) + Docetaxel as Second-Line Therapy in Patients With Stage IIIB/IV or Recurrent NSCLC: Results of the Phase III, Randomised,
Double-Blind LUME-Lung 1 Trial

http://www.boehringer-ingelheim. ... LCC_LUME-Lung_1.pdf

costa_na · 发表于 2014-7-4 14:43:19

Retrospective Evaluation of the Futility Analysis in LUME-Lung 2, a Randomised, Double-blind, Placebo-controlled Phase III Trial of Nintedanib (BIBF 1120) in Combination with Pemetrexed in NSCLC Patients Progressing after One Prior First-line Chemotherapy

costa_na · 发表于 2014-7-4 14:43:57

本帖最后由 costa_na 于 2014-7-4 14:45 编辑

Identification of a Clinical Biomarker for Second-line Combination Treatment with Nintedanib in Adenocarcinoma Non-small Cell Lung Cancer (NSCLC) Patients in Two Phase III Trials

costa_na · 发表于 2014-7-4 14:48:35

Phase I Study of Oral Nintedanib Combined with Docetaxel in Previously Treated Japanese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

nintedanib_okamoto_119929_P415.pdf (856.92 KB, 下载次数: 90)

costa_na · 发表于 2014-7-4 14:50:08

Nintedanib (BIBF 1120) plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma—an international, multicenter, randomized, double-blind, placebo-controlled phase II study

ASCO_2014_-_Meso_Poster.pdf (779.59 KB, 下载次数: 79)